OBJECTIVE: To evaluate the efficiency of series of 6-week treatments with brief intervals (6-week = 1 cycle) of topical Interferon a-2b ( @entity4020 ) treatment in @entity1709 ( @entity1709 ) with atypia and @entity320 . @entity1 AND METHODS: Five @entity1 with biopsy-proven @entity1709 with atypia and seven @entity1 with @entity320 , treated with topical @entity4020 (1 million units/ml, 5 times daily), were included in the study. All @entity1 had colour photographs and the @entity5 area was measured manually for each @entity1 before and after treatment. RESULTS: The median age of 12 @entity1 at initiation of treatment was 61.5 years (range 39-75 years). The mean therapy duration was 2.4 cycles (range 1-6 cycle). Compared to pretreatment lesion dimension, the mean decrease in @entity5 size were after the first cycle 66% (range 18-98%; p = 0.004; n = 10 @entity1 ), after the second cycle 55% (range 10-100%; p = 0.016; n = 7 @entity1 ), and after the third cycle 74% (range 23-100%; n = 3 @entity1 ). In one @entity1 6 cycles of topical @entity4020 were needed. The decrease in size was 22% after the 4(th) cycle, 34% after the 5(th) cycle, and 98% after the 6(th) cycle. CONCLUSION: Our clinical experience demonstrates promising results of topical @entity4020 treatment for @entity1709 with atypia and @entity320 without any local or systemic side effects. However, future multicenter prospective studies are recommended to confirm the efficiency and safety of topical @entity4020 treatment.

Evaluation of a short-term topical interferon a-2b treatment for histologically proven XXXX and @entity1709 with atypia.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity1709 :: ('MESH:D008548', 'Disease') :: ['primary acquired melanosis', 'PAM'] @entity4020 :: ('3440', 'Gene') :: ['IFNa-2b'] @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma of the conjunctiva']
@entity320 :: (MESH:D008545,Disease) :: ['melanoma']
